Continuous Glucose Monitoring and Use of Alternative Markers To Assess Glycemia in Chronic Kidney Disease

In chronic kidney disease, glycated albumin and fructosamine have been postulated to be better biomarkers of glycemic control than HbA . We evaluated the accuracy, variability, and covariate bias of three biomarkers (HbA , glycated albumin, and fructosamine) compared with continuous glucose monitori...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Diabetes care 2020-10, Vol.43 (10), p.2379-2387
Hauptverfasser:	Zelnick, Leila R, Batacchi, Zona O, Ahmad, Iram, Dighe, Ashveena, Little, Randie R, Trence, Dace L, Hirsch, Irl B, de Boer, Ian H
Format:	Artikel
Sprache:	eng
Schlagworte:	Albumin Albumins Bias Biomarkers Blood glucose Clinical Care/Education/Nutrition/Psychosocial Research Colorimetry Diabetes Diabetes mellitus Diabetes mellitus (non-insulin dependent) Dialysis Epidermal growth factor receptors Glomerular filtration rate Glucose Glucose monitoring Kidney diseases Kidneys Monitoring Research design Telemedicine Transferrin Transferrins Variability
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	In chronic kidney disease, glycated albumin and fructosamine have been postulated to be better biomarkers of glycemic control than HbA . We evaluated the accuracy, variability, and covariate bias of three biomarkers (HbA , glycated albumin, and fructosamine) compared with continuous glucose monitoring (CGM)-derived measurement of glycemia across estimated glomerular filtration rate (eGFR) in type 2 diabetes. A prospective cohort study was conducted of 104 participants with type 2 diabetes, 80 with eGFR
ISSN:	0149-5992 1935-5548
DOI:	10.2337/dc20-0915